Cargando…

Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report

Variant acute promyelocytic leukemia (APL) showed quite different aspects, and the current treatments remained challenged at present. Venetoclax, a selective inhibitor of B-cell lymphoma 2 (BCL-2), is a small molecule that has been studied in several hematologic malignancies as both monotherapy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Baoquan, Wang, Xin, Kong, Xin, Wang, Man, Yao, Li, Shen, Hongjie, Zhang, Jian, Qiu, Huiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858936/
https://www.ncbi.nlm.nih.gov/pubmed/35198449
http://dx.doi.org/10.3389/fonc.2022.828852
_version_ 1784654341716574208
author Song, Baoquan
Wang, Xin
Kong, Xin
Wang, Man
Yao, Li
Shen, Hongjie
Zhang, Jian
Qiu, Huiying
author_facet Song, Baoquan
Wang, Xin
Kong, Xin
Wang, Man
Yao, Li
Shen, Hongjie
Zhang, Jian
Qiu, Huiying
author_sort Song, Baoquan
collection PubMed
description Variant acute promyelocytic leukemia (APL) showed quite different aspects, and the current treatments remained challenged at present. Venetoclax, a selective inhibitor of B-cell lymphoma 2 (BCL-2), is a small molecule that has been studied in several hematologic malignancies as both monotherapy and in combination with other agents. However, there is little of its use in the treatment of APL or variant APL. In this report, we identified THRAP3 as novel RARA fusion in resembling APL, which was resistant to all-trans retinoic acid (ATRA) combined arsenic trioxide (ATO) chemotherapy. Then, the patient was salvaged by low-dose venetoclax and decitabine. The treatment in this case demonstrates the potential ability of venetoclax in variant APL, thus providing a new treatment option for all kinds of APL.
format Online
Article
Text
id pubmed-8858936
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88589362022-02-22 Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report Song, Baoquan Wang, Xin Kong, Xin Wang, Man Yao, Li Shen, Hongjie Zhang, Jian Qiu, Huiying Front Oncol Oncology Variant acute promyelocytic leukemia (APL) showed quite different aspects, and the current treatments remained challenged at present. Venetoclax, a selective inhibitor of B-cell lymphoma 2 (BCL-2), is a small molecule that has been studied in several hematologic malignancies as both monotherapy and in combination with other agents. However, there is little of its use in the treatment of APL or variant APL. In this report, we identified THRAP3 as novel RARA fusion in resembling APL, which was resistant to all-trans retinoic acid (ATRA) combined arsenic trioxide (ATO) chemotherapy. Then, the patient was salvaged by low-dose venetoclax and decitabine. The treatment in this case demonstrates the potential ability of venetoclax in variant APL, thus providing a new treatment option for all kinds of APL. Frontiers Media S.A. 2022-02-07 /pmc/articles/PMC8858936/ /pubmed/35198449 http://dx.doi.org/10.3389/fonc.2022.828852 Text en Copyright © 2022 Song, Wang, Kong, Wang, Yao, Shen, Zhang and Qiu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Song, Baoquan
Wang, Xin
Kong, Xin
Wang, Man
Yao, Li
Shen, Hongjie
Zhang, Jian
Qiu, Huiying
Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report
title Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report
title_full Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report
title_fullStr Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report
title_full_unstemmed Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report
title_short Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report
title_sort clinical response to venetoclax and decitabine in acute promyelocytic leukemia with a novel rara-thrap3 fusion: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858936/
https://www.ncbi.nlm.nih.gov/pubmed/35198449
http://dx.doi.org/10.3389/fonc.2022.828852
work_keys_str_mv AT songbaoquan clinicalresponsetovenetoclaxanddecitabineinacutepromyelocyticleukemiawithanovelrarathrap3fusionacasereport
AT wangxin clinicalresponsetovenetoclaxanddecitabineinacutepromyelocyticleukemiawithanovelrarathrap3fusionacasereport
AT kongxin clinicalresponsetovenetoclaxanddecitabineinacutepromyelocyticleukemiawithanovelrarathrap3fusionacasereport
AT wangman clinicalresponsetovenetoclaxanddecitabineinacutepromyelocyticleukemiawithanovelrarathrap3fusionacasereport
AT yaoli clinicalresponsetovenetoclaxanddecitabineinacutepromyelocyticleukemiawithanovelrarathrap3fusionacasereport
AT shenhongjie clinicalresponsetovenetoclaxanddecitabineinacutepromyelocyticleukemiawithanovelrarathrap3fusionacasereport
AT zhangjian clinicalresponsetovenetoclaxanddecitabineinacutepromyelocyticleukemiawithanovelrarathrap3fusionacasereport
AT qiuhuiying clinicalresponsetovenetoclaxanddecitabineinacutepromyelocyticleukemiawithanovelrarathrap3fusionacasereport